Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial by Takashi Kadowaki, Masaomi Nangaku, Stefan Hantel, Tomoo Okamura, Maximilian vonEynatten, Christoph Wanner, Audrey Koitka‐Weber

Get full text

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial by João Pedro Ferreira, Bettina Johanna Kraus, Isabella Zwiener, Sabine Lauer, Bernard Zinman, David H. Fitchett, Audrey Koitka‐Weber, Jyothis T. George, Anne Pernille Ofstad, Christoph Wanner, Faiez Zannad

Get full text

Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial by Simke W. Waijer, Di Xie, Silvio E. Inzucchi, Bernard Zinman, Audrey Koitka‐Weber, Michaela Mattheus, Maximillian von Eynatten, Lesley A. Inker, Christoph Wanner, Hiddo J. L. Heerspink

Get full text

Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease by Anna M. D. Watson, Anna M. D. Watson, Eleanor A. M. Gould, Sarah C. Moody, Priyadharshini Sivakumaran, Karly C. Sourris, Bryna S. M. Chow, Audrey Koïtka-Weber, Terri J. Allen, Karin A. M. Jandeleit-Dahm, Karin A. M. Jandeleit-Dahm, Mark E. Cooper, Mark E. Cooper, Anna C. Calkin, Anna C. Calkin

Get full text